Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center in Buffalo, NY, shares a brief overview of AML and discusses how the treatment landscape for patients with AML has changed in recent years.
Click here to learn more.
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, discusses acute myeloid leukemia (AML) in the context of the COVID-19 pandemic. The prevalence of healthcare disparities…
In this episode of The AML Expert Series, Amer Zeidan, MBBS, Yale School of Medicine, New Haven, Connecticut, and Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center,…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
In this webcast symposium, Gail J. Roboz, MD, professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University…
Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…
Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet…
In this panel discussion from the 7th International Workshop on Acute Leukemias, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Andrew Wei, MBBS, PhD, Peter MacCallum…
Stephen Strickland, MD, Sarah Cannon Research Institute, AML patient and neurologist Dr Joseph, and patient advocate Steve Buechler discuss the critical role of molecular and genetic testing in…
Alice S. Mims, MD, of The Ohio State University’s James Comprehensive Cancer Center, provided an overview of current AML treatment options, such as FLT3 and IDH inhibitors, while…
